The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

Imagion Biosystems (ASX: IBX) has announced it will fast-track a new batch of MagSense HER2 imaging agent ahead of a Phase 2 ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

Olivia Munn is opening up about her mom's breast cancer diagnosis. The "Your Friends and Neighbors" star, 45, took to ...

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs treatment sequencing.

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for HER2 testing if the cancer is invasive, metastatic, and/or recurrent.